Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An adjuvant for desensitization vaccine and a new type of desensitization vaccine

A vaccine and desensitization technology, applied to allergic diseases, medical preparations containing active ingredients, antibody medical ingredients, etc., can solve problems such as inability to induce immune tolerance

Active Publication Date: 2021-04-27
CHENGDU MAXVAX BIOTECHNOLOGY LLC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chen Dexiang and others published a paper in the journal "Clinical Immunology of Allergy", proving that common adjuvants for vaccines to prevent infectious diseases, such as CpG gene sequences, can stimulate inflammation at the injection site and promote the maturation of antigen-presenting cells, but cannot induce immune resistance. by

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An adjuvant for desensitization vaccine and a new type of desensitization vaccine
  • An adjuvant for desensitization vaccine and a new type of desensitization vaccine
  • An adjuvant for desensitization vaccine and a new type of desensitization vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050]The desensitization vaccine formulation in Example 1 is a glucocorticoid (acetic acid dexamethasone) and egg white protein, and the vaccine is applied to the skin, and the inflammatory cytokine production of skin cells can be suppressed. Such asfigure 1 As shown, the level of inflammatory cytokines produced by the skin of the application of the drug. In Example 1, the application of the desensitization treatment group contained the egg white protein and glucocorticoid; the application of the standard treatment group only contains only the compound white protein; the apparest for the unprocessed group was physiological saline.

[0051]Example 1 The test uses 6 to 8 weeks large female BALB / C mice. Abdominal skin hair of mice shaved, rest for 24 hours. The desensitization treatment group mice were applied to hair removal skin; the second day, the liquid of the egg white protein was applied to the same part of the skin surface - the skin can be complete Or sandpaper treatment of ep...

Embodiment 2

[0056]Example 2 The dust mite allergy and desensitization treatment model of mice were established.

[0057]This test uses a 6 to 8 weeks of female C57BL / 6 mice (Charles River), or Balles River. The allergic model of the mouse involves two steps of sensitization and attack. The step of sensitization is to inject 50 μg of dust mites (adsorbed on the surface of 1 mg of aluminum hydroxide) in mice. The amount of injection is 0.5 ml. At 14 days, attack. The step of attacking the drug is to enter the lungs 10 μg HDM (HDM is dust mite extract) in the mouse driver. 48 hours in repeated attack once. After 24 hours of the second attack, carbon dioxide was used to eat mice. Bronchial alveolar lavewater (BALF) was collected, and the counting of various types of cells and cytokine analysis were collected, and the lung tissue was collected.

[0058]After the death of mice, the pulmonary was washed 3 times with 1 ml of sterile brine. The pulmonary washed liquid, and the supernatant was stored at -80 ...

Embodiment 3

[0061]Example 3 utilizes a desensitization vaccine containing a glucocorticoid and an indoor dust mites, an allergic mouse obtained by immunotherapy is effective, reducing dust mites induced by immunotherapy. Such asfigure 2 Due to the mouse model of dust mites, desensitization treatment affects eosinophils in lung intracellularophilic in the lungs. The application of the desensitization treatment group is a dust mite extract, and the application of the glucocorticoid, the application of the standard treatment group contains only dust mites extract, and the application of the unreamped group is physiological saline. By using a desensitization vaccine containing glucocorticoid and indoor dust mites, mouse respiratory inflammation is reduced, especially the number of eosinophils in the lung, especially the number of eosinophils in the lung.image 3 Due to the mouse model of dust mites, desensitization therapy on the influence of pulmonary cytokines. Dental treatment group of allergens ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an adjuvant for a desensitization vaccine, which includes an immune tolerance-inducing component, and the immune tolerance-inducing component is an anti-inflammatory compound. The present invention also provides a novel desensitizing vaccine using an anti-inflammatory compound as an adjuvant. In the present invention, the anti-inflammatory compound is used as an adjuvant and co-injected with the allergen to prevent the inflammation of the allergic vaccine at the site; the anti-inflammatory compound has the effect of inhibiting the maturation of antigen-presenting cells, and the anti-inflammatory compound directly acts on the antigen-presenting cells, inhibiting They become mature cells during antigen uptake and presentation; anti-inflammatory compounds achieve long-lasting treatment of allergies by rapidly inducing the generation of Treg cells. The desensitization vaccine provided by the invention can realize rapid, long-acting and effective treatment of allergic symptoms from the mechanism of sensitization.

Description

Technical field[0001]The present invention relates to a vaccine and its adjuvant, and more particularly to a desensitized vaccine and its adjuvant.Background technique[0002]Allergies are hypersensitivity to the immune system to be harmless in the environment. Common reasons for allergies mainly include indoor dust mites, plant pollen, mold, drug, food, animal dandruff and insect venom. Immunotherapy can relieve symptoms for a long time, preventing disease from rhinitis to allergic asthma development, and even cure. The process of allergic occurs includes sensitization phase and allergic reaction stage. In the sensitization stage, an immunization reaction occurs when the body is exposed to allergens, thereby producing a large number of T-type T-assisted lymphocytes (T Helper 2, TH2) and IgE antibodies for specific allergens. The IgE antibody binds to receptors of the surface of the primary cells and basophilic cells in the respiratory mucosa or skin. After the body is sensitive, an a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K45/00A61K31/573A61K39/35A61K39/36A61P37/08
CPCA61K31/573A61K39/35A61K39/36A61K39/39A61K45/00A61K2039/55511
Inventor 陈德祥董丽春
Owner CHENGDU MAXVAX BIOTECHNOLOGY LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products